[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE050264T2 - Eljárások transzdukálásra és sejtfeldolgozásra - Google Patents

Eljárások transzdukálásra és sejtfeldolgozásra

Info

Publication number
HUE050264T2
HUE050264T2 HUE15802231A HUE15802231A HUE050264T2 HU E050264 T2 HUE050264 T2 HU E050264T2 HU E15802231 A HUE15802231 A HU E15802231A HU E15802231 A HUE15802231 A HU E15802231A HU E050264 T2 HUE050264 T2 HU E050264T2
Authority
HU
Hungary
Prior art keywords
transduction
methods
cell processing
cell
processing
Prior art date
Application number
HUE15802231A
Other languages
English (en)
Inventor
Ryan Crisman
Chris Ramsborg
Travis Wood
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of HUE050264T2 publication Critical patent/HUE050264T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
    • B04B—CENTRIFUGES
    • B04B7/00—Elements of centrifuges
    • B04B7/08—Rotary bowls
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
HUE15802231A 2014-11-05 2015-11-04 Eljárások transzdukálásra és sejtfeldolgozásra HUE050264T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462075801P 2014-11-05 2014-11-05
US201562129023P 2015-03-05 2015-03-05

Publications (1)

Publication Number Publication Date
HUE050264T2 true HUE050264T2 (hu) 2020-11-30

Family

ID=54754736

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15802231A HUE050264T2 (hu) 2014-11-05 2015-11-04 Eljárások transzdukálásra és sejtfeldolgozásra

Country Status (29)

Country Link
US (3) US10428351B2 (hu)
EP (3) EP3215601B1 (hu)
JP (4) JP6740234B2 (hu)
KR (2) KR102635942B1 (hu)
CN (2) CN113736828A (hu)
AU (3) AU2015343121B2 (hu)
BR (2) BR122020002722B1 (hu)
CA (1) CA2966538A1 (hu)
CY (1) CY1123254T1 (hu)
DK (2) DK3757206T3 (hu)
ES (2) ES2805674T3 (hu)
FI (1) FI3757206T3 (hu)
HR (1) HRP20201128T1 (hu)
HU (1) HUE050264T2 (hu)
IL (2) IL292450A (hu)
LT (1) LT3215601T (hu)
MA (1) MA40318A (hu)
MX (3) MX2017005823A (hu)
MY (1) MY186199A (hu)
NZ (2) NZ769598A (hu)
PH (1) PH12017500824A1 (hu)
PL (2) PL3215601T3 (hu)
PT (2) PT3215601T (hu)
RS (1) RS60685B1 (hu)
SG (2) SG10202002324SA (hu)
SI (1) SI3215601T1 (hu)
SM (1) SMT202000397T1 (hu)
TW (3) TW202315948A (hu)
WO (1) WO2016073602A2 (hu)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
CN113046312A (zh) 2014-04-23 2021-06-29 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
EP3932950A1 (en) 2014-10-20 2022-01-05 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
SG10202002324SA (en) 2014-11-05 2020-05-28 Juno Therapeutics Inc Methods for transduction and cell processing
CN107106744B (zh) * 2014-12-19 2020-12-01 生物安全股份有限公司 生物流体的顺序处理
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
BR112017024757A2 (pt) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr utilizando proteínas de fusão
CN108474002B (zh) 2015-10-22 2023-05-23 朱诺治疗学有限公司 用于转导的方法、反应剂盒、反应剂和设备
US20170198303A1 (en) 2015-12-04 2017-07-13 Emory University Methods, Devices and Systems for Enhanced Transduction Efficiency
CA3016871A1 (en) * 2016-03-07 2017-09-14 Hitachi Chemical Advanced Therapeutics Solutions, LLC A closed system for labelling and selecting live cells
WO2017161212A1 (en) 2016-03-16 2017-09-21 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
AU2017301887A1 (en) 2016-07-29 2019-02-07 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-CD19 antibodies
US11242376B2 (en) 2016-08-02 2022-02-08 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CN109890952A (zh) 2016-09-12 2019-06-14 朱诺治疗学股份有限公司 灌注生物反应器袋装配
KR20190058509A (ko) 2016-10-07 2019-05-29 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 t-세포 수용체 리프로그래밍을 위한 조성물 및 방법
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
US20200095547A1 (en) * 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
US20190350978A1 (en) * 2016-12-05 2019-11-21 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
MX2019010171A (es) 2017-02-27 2019-10-15 Juno Therapeutics Inc Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
US20200077644A1 (en) 2017-03-14 2020-03-12 Juno Therapeutics, Inc. Methods for cryogenic storage
EP3427052A4 (en) * 2017-03-27 2019-12-04 Hitachi Chemical Advanced Therapeutics Solutions, LLC CLOSED SYSTEM FOR MARKING AND SELECTING LIVING CELLS
CN110494557A (zh) 2017-03-27 2019-11-22 新加坡国立大学 用于离体扩增和活化自然杀伤细胞的刺激细胞系
KR20240057444A (ko) 2017-03-27 2024-05-02 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
KR20200054160A (ko) * 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
AU2018310452A1 (en) 2017-07-29 2020-02-13 Juno Therapeutics, Inc. Reagents for expanding cells expressing recombinant receptors
WO2019046766A2 (en) * 2017-09-01 2019-03-07 Lonza Walkersville, Inc. AUTOMATION OF CELLULAR THERAPY FROM END TO END
US20200292526A1 (en) 2017-09-07 2020-09-17 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
EP3704230B1 (en) * 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
SG11202003657VA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Process for producing a t cell composition
MA50571A (fr) 2017-11-10 2020-09-16 Juno Therapeutics Inc Réservoirs cryogéniques à système fermé
MA51114A (fr) 2017-12-08 2020-10-14 Juno Therapeutics Inc Procédé de production d'une compositions de lymphocytes t modifiés
BR112020011223A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc marcadores fenotípicos para terapia celular e mé-todos relacionados
MA51105A (fr) 2017-12-08 2020-10-14 Juno Therapeutics Inc Formulation de milieux sans sérum pour la culture de cellules et ses procédés d'utilisation
BR112020016176A2 (pt) 2018-02-09 2022-02-22 Immatics Us Inc Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
IL313701A (en) 2018-08-09 2024-08-01 Juno Therapeutics Inc Processes for creating transgenic cells and their compounds
CN112805378A (zh) 2018-08-09 2021-05-14 朱诺治疗学股份有限公司 用于评估整合核酸的方法
MA53612A (fr) 2018-09-11 2021-09-15 Juno Therapeutics Inc Procédés d'analyse par spectrométrie de masse de compositions cellulaires modifiées
KR20210098450A (ko) 2018-10-31 2021-08-10 주노 테라퓨틱스 게엠베하 세포의 선택 및 자극을 위한 방법 및 이를 위한 장치
MX2021005024A (es) 2018-11-01 2021-07-21 Juno Therapeutics Inc Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b.
JP2022008735A (ja) * 2018-11-06 2022-01-14 テルモ株式会社 細胞製造システム、細胞製造方法、医療装置及び医療デバイス
ES2968737T3 (es) 2018-11-06 2024-05-13 Juno Therapeutics Inc Proceso para producir células T manipuladas genéticamente
KR20210104713A (ko) 2018-11-16 2021-08-25 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
DK3886894T3 (da) 2018-11-30 2024-06-03 Juno Therapeutics Inc Fremgangsmåder til dosering og behandling af b-cellemaligniteter i adoptiv celleterapi
US20220088070A1 (en) 2018-11-30 2022-03-24 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
WO2020114491A1 (en) * 2018-12-07 2020-06-11 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for immunotherapy
US11714096B2 (en) 2018-12-21 2023-08-01 Octane Biotech Inc. Carousel for modular biologic production units
CA3123449A1 (en) 2018-12-21 2020-06-25 Lonza Walkersville, Inc. Automated production of viral vectors
US11773365B2 (en) 2019-02-08 2023-10-03 Lonza Walkersville, Inc. Cell concentration methods and devices for use in automated bioreactors
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2020196412A1 (ja) * 2019-03-26 2020-10-01 テルモ株式会社 遠心部材及び洗浄方法
EP3980530A1 (en) 2019-06-07 2022-04-13 Juno Therapeutics, Inc. Automated t cell culture
JP7343881B2 (ja) * 2019-06-10 2023-09-13 アイ ピース，インコーポレイテッド 赤血球除去装置、単核球回収器、細胞培養装置、細胞培養システム、細胞培養方法、及び単核球の回収方法
MX2021015317A (es) 2019-06-12 2022-03-11 Juno Therapeutics Inc Terapia de combinacion de una terapia citotoxica mediada por celulas y un inhibidor de una proteina de la familia bcl2 de prosupervivencia.
JP2022545467A (ja) 2019-08-22 2022-10-27 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
EP4022637A2 (en) 2019-08-30 2022-07-06 Juno Therapeutics, Inc. Machine learning methods for classifying cells
AU2020369940A1 (en) 2019-10-21 2022-05-26 Flaskworks, Llc Systems and methods for cell culturing
MX2022005145A (es) 2019-10-30 2022-06-29 Juno Therapeutics Gmbh Dispositivos de estimulación y/o selección celular y método de uso.
CN115087868A (zh) 2019-11-05 2022-09-20 朱诺治疗学股份有限公司 确定治疗性t细胞组合物的属性的方法
US12163146B2 (en) 2019-11-11 2024-12-10 Lonza Walkersville, Inc. Quality control methods for automated cell processing
JP7605840B2 (ja) 2019-12-06 2024-12-24 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞性悪性疾患を処置するための細胞療法と関連する毒性および奏効に関係する方法
US20230192869A1 (en) 2019-12-06 2023-06-22 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
JP2023504740A (ja) 2019-12-06 2023-02-06 ジュノー セラピューティクス インコーポレイテッド Ｂｃｍａ標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
CN115003818A (zh) * 2020-01-22 2022-09-02 科济生物医药（上海）有限公司 病毒载体转导细胞的方法
KR20220145341A (ko) 2020-01-24 2022-10-28 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법에서 여포성 림프종 및 변연부 림프종의 투여 및 치료 방법
WO2021154887A1 (en) 2020-01-28 2021-08-05 Juno Therapeutics, Inc. Methods for t cell transduction
AU2021217829A1 (en) * 2020-02-06 2022-08-18 Cutiss Ag Cell isolation device and method
CN115768443A (zh) 2020-02-12 2023-03-07 朱诺治疗学股份有限公司 Cd19定向嵌合抗原受体t细胞组合物和方法及其用途
AU2021219764A1 (en) 2020-02-12 2022-09-01 Juno Therapeutics, Inc. BCMA-directed chimeric antigen receptor T cell compositions and methods and uses thereof
WO2021202980A1 (en) * 2020-04-03 2021-10-07 Millennium Pharmaceuticals, Inc. Enhanced viral transduction efficiency
MX2022012533A (es) 2020-04-10 2022-12-13 Juno Therapeutics Inc Metodos y usos relacionados con terapia celular dise?ada con un receptor de antigeno quimerico dirigido al antigeno de maduracion de celulas b.
CN115835873A (zh) 2020-05-13 2023-03-21 朱诺治疗学股份有限公司 用于产生表达重组受体的供体分批细胞的方法
JP2023528215A (ja) 2020-05-13 2023-07-04 ジュノー セラピューティクス インコーポレイテッド 臨床応答に関連する特徴量の特定方法およびその使用
US20230324408A1 (en) 2020-08-05 2023-10-12 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
US20220265719A1 (en) 2021-02-20 2022-08-25 Kite Pharma, Inc. Immunotherapies
US20240168012A1 (en) 2021-03-22 2024-05-23 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
KR20230158573A (ko) 2021-03-22 2023-11-20 주노 쎄러퓨티크스 인코퍼레이티드 바이러스 벡터 입자의 효력을 평가하는 방법
KR20240005700A (ko) 2021-03-29 2024-01-12 주노 쎄러퓨티크스 인코퍼레이티드 체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
AU2022274608A1 (en) 2021-05-14 2023-11-09 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
WO2023159001A1 (en) 2022-02-15 2023-08-24 Kite Pharma, Inc. Predicting adverse events from immunotherapy
WO2023225569A1 (en) 2022-05-17 2023-11-23 Umoja Biopharma, Inc. Manufacturing viral particles
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
WO2024097992A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
WO2024098038A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Polynucleotide construct and related viral vectors and methods
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024145732A1 (zh) * 2023-01-03 2024-07-11 深圳华大生命科学研究院 分选流体系统及相关设备、流体分选方法及细胞分选方法
WO2024182516A1 (en) 2023-02-28 2024-09-06 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
WO2024238153A1 (en) 2023-05-15 2024-11-21 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163519A (en) 1977-11-01 1979-08-07 Union Carbide Corporation Compensating rotor
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (hu) 1986-08-07 1989-12-23 Battelle Memorial Institute
SE454413B (sv) 1986-09-12 1988-05-02 Alfa Laval Separation Ab Centrifugalseparator med en rotor, vari ett bojligt organ strecker sig ett stycke lengs rotorns omkrets
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
US5911983A (en) * 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
CA2163427A1 (en) 1993-05-21 1994-12-08 Stephen D. Lupton Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5437998A (en) * 1993-09-09 1995-08-01 Synthecon, Inc. Gas permeable bioreactor and method of use
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
JP2000501614A (ja) 1995-12-15 2000-02-15 システミックス，インコーポレイテッド 高形質導入効率を有するレトロウイルスベクター上清を得るための方法
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US6123655A (en) * 1996-04-24 2000-09-26 Fell; Claude Cell separation system with variable size chamber for the processing of biological fluids
EP0995802B1 (en) * 1998-07-10 2009-12-23 Universite Pierre Et Marie Curie Method for the delivery of nucleic acids to cells in vitro or ex vivo
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
DE69919029T2 (de) 1998-12-24 2005-09-08 Biosafe S.A. Vorrichtung zur bluttrennung, insbesondere zur konzentrierung von hematopoietischen stammzellen
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
WO2001094944A2 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
DE60122765D1 (de) 2000-11-07 2006-10-12 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
DE10136375A1 (de) 2001-07-26 2003-02-13 Cellgenix Technologie Transfer Verfahren zur Anreicherung von Zellen
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7001513B2 (en) 2003-08-06 2006-02-21 Nuvue Technologies, Inc. Automated processing of a biological component
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
ES2345837T3 (es) 2005-03-23 2010-10-04 Biosafe S.A. Sistema integrado para la recogida, el procesamiento y el trasplante de subgrupos de celulas, incluyendo celulas madre adultas, para medicina regenerativa.
JP5453629B2 (ja) * 2006-08-23 2014-03-26 タカラバイオ株式会社 遠心用袋状容器を使用した遺伝子導入方法
EP2537416B1 (en) 2007-03-30 2014-11-12 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
ES2660180T3 (es) * 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
JP5746025B2 (ja) 2008-07-16 2015-07-08 ケーセップ・システムズ，リミテッド・ライアビリティ・カンパニー 流動床を使用して粒子を操作するための方法及びシステム
EP4049674A1 (en) 2009-11-03 2022-08-31 City of Hope Truncated epidermal growth factor receptor (egfrt) for transduced t cell selection
AU2011227203B2 (en) 2010-03-18 2017-01-05 Thermogenesis Corp. System for purifying certain cell populations in blood or bone marrow by depleting others
SE535275C2 (sv) 2010-03-31 2012-06-12 Alfa Laval Corp Ab Centrifugalseparator och rotor
ES2550484T3 (es) * 2010-07-15 2015-11-10 Terumo Bct, Inc. Método de optimización del tiempo de centrifugación en un aparato centrifugador para fluidos biológicos
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX2013008376A (es) * 2011-01-18 2013-08-12 Univ Pennsylvania Composiciones y metodos para el tratamiento de cancer.
NZ743310A (en) 2011-03-23 2022-11-25 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
EP2714886B1 (en) * 2011-05-30 2020-01-22 Atech Partners Ltd. Bioreactor system for continuous cell cultivation
CN102329776B (zh) * 2011-07-20 2013-02-27 华中农业大学 一种表达Nectin-1基因胞外区片段的PK-15细胞系及其构建方法
JP6053688B2 (ja) * 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2594632A1 (en) * 2011-11-18 2013-05-22 Miltenyi Biotec GmbH Method and device for cell modification
ES2774160T3 (es) 2012-02-13 2020-07-17 Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
AU2013224027B2 (en) * 2012-02-23 2019-01-24 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP2820138B1 (en) 2012-02-29 2020-10-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Retroviral transduction using poloxamers
US10066213B2 (en) 2012-03-13 2018-09-04 Emd Millipore Corporation Use of centrifugation-aided infection to increase virus titer
CN104395462B (zh) 2012-05-03 2017-09-26 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
EP3276000A3 (en) * 2012-05-25 2018-02-21 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
EP2698208A1 (de) 2012-08-14 2014-02-19 Fresenius Kabi Deutschland GmbH Zentrifugenvorrichtung und Verfahren zum Betreiben einer Zentrifugenvorrichtung
EP3824905B1 (en) 2012-08-20 2025-01-08 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
AU2014225365B2 (en) * 2013-03-07 2019-09-12 Baylor College Of Medicine Targeting CD138 in cancer
TWI654206B (zh) * 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
AU2014248119B2 (en) * 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
SG11201603228TA (en) 2013-10-31 2016-05-30 Hutchinson Fred Cancer Res Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
CN113046312A (zh) 2014-04-23 2021-06-29 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
ES2708584T3 (es) 2014-04-24 2019-04-10 Miltenyi Biotec Gmbh Método para la generación automatizada de células T modificadas genéticamente
SG10202002324SA (en) 2014-11-05 2020-05-28 Juno Therapeutics Inc Methods for transduction and cell processing
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée

Also Published As

Publication number Publication date
EP4407036A2 (en) 2024-07-31
AU2020233623A1 (en) 2020-10-08
MX2017005823A (es) 2017-08-02
BR112017009220B1 (pt) 2022-04-12
JP7202332B2 (ja) 2023-01-11
EP3215601B1 (en) 2020-05-27
NZ769595A (en) 2023-06-30
HRP20201128T1 (hr) 2020-10-30
NZ769598A (en) 2023-05-26
CN113736828A (zh) 2021-12-03
LT3215601T (lt) 2020-08-25
MX2022000159A (es) 2022-02-21
FI3757206T3 (fi) 2024-06-19
KR102635942B1 (ko) 2024-02-14
PH12017500824A1 (en) 2017-10-18
TW201636427A (zh) 2016-10-16
CA2966538A1 (en) 2016-05-12
IL252126B (en) 2022-06-01
SG11201703656PA (en) 2017-06-29
ES2987570T3 (es) 2024-11-15
AU2020233623B2 (en) 2022-08-04
JP2017535282A (ja) 2017-11-30
SG10202002324SA (en) 2020-05-28
SI3215601T1 (sl) 2020-08-31
IL292450A (en) 2022-06-01
TWI787903B (zh) 2022-12-21
AU2022263539A1 (en) 2023-02-23
ES2805674T3 (es) 2021-02-15
DK3215601T3 (da) 2020-06-15
TWI735418B (zh) 2021-08-11
KR20240023204A (ko) 2024-02-20
US11802295B2 (en) 2023-10-31
MA40318A (fr) 2017-09-13
DK3757206T3 (da) 2024-07-15
EP4407036A3 (en) 2024-10-23
PL3757206T3 (pl) 2024-07-08
NZ732130A (en) 2021-11-26
TW202208633A (zh) 2022-03-01
JP6740234B2 (ja) 2020-08-12
BR122020002722B1 (pt) 2022-06-07
EP3757206A1 (en) 2020-12-30
PL3215601T3 (pl) 2020-11-02
WO2016073602A3 (en) 2016-06-30
US10428351B2 (en) 2019-10-01
EP3757206B1 (en) 2024-04-10
BR112017009220A2 (pt) 2017-12-26
US20160122782A1 (en) 2016-05-05
AU2015343121B2 (en) 2020-06-18
JP2020182488A (ja) 2020-11-12
US20240011051A1 (en) 2024-01-11
JP2024159813A (ja) 2024-11-08
KR20170092567A (ko) 2017-08-11
CN107109438A (zh) 2017-08-29
MY186199A (en) 2021-06-30
SMT202000397T1 (it) 2020-09-10
AU2015343121A1 (en) 2017-05-18
RS60685B1 (sr) 2020-09-30
US20190376084A1 (en) 2019-12-12
IL252126A0 (en) 2017-07-31
JP2023024691A (ja) 2023-02-16
AU2022263539B2 (en) 2024-12-05
EP3215601A2 (en) 2017-09-13
PT3215601T (pt) 2020-08-03
MX2021001334A (es) 2021-04-12
TW202315948A (zh) 2023-04-16
CN107109438B (zh) 2021-09-03
WO2016073602A2 (en) 2016-05-12
PT3757206T (pt) 2024-05-21
CY1123254T1 (el) 2021-10-29

Similar Documents

Publication Publication Date Title
HUE050264T2 (hu) Eljárások transzdukálásra és sejtfeldolgozásra
HK1250481A1 (zh) 經過修飾的t細胞及其製備和使用方法
HK1243333A1 (zh) 用於修飾的t細胞的方法和組合物
HUE050355T2 (hu) Claudin-6-specifikus immunreceptorok és T-sejt-epitópok
HUE055473T2 (hu) Difluormetil-aminopiridinek és difluormetil-aminopirimidinek
HUE052771T2 (hu) C10orf54 elleni antitestek és alkalmazásuk
PL3560953T3 (pl) Komórka
HUE055755T2 (hu) Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3149042T3 (da) PD-L1-antistoffer og anvendelser deraf
HUE045872T2 (hu) Sejteket penetráló peptidek és ezek elõállítására és alkalmazására szolgáló eljárások
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
HUE055221T2 (hu) Tetrahidropiranil amino-pirrolopirimidinon és eljárások annak felhasználására
IL249970B (en) Gamma delta t cells and uses thereof
LT3230463T (lt) Greitas apdorojimas
DK3156503T3 (da) Mavecancer-biomarkør og detektionsfremgangsmåde
DK3101760T3 (da) Opladningsfremgangsmåde og system
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
EP2998732C0 (en) Analysis method
HUE065961T2 (hu) Audió kódoló eszköz és audió kódolási eljárás
DK3131577T3 (da) Modificerede værtsceller og anvendelser deraf
HUE058705T2 (hu) Herbicidtolerancia-gének és eljárások ezek alkalmazására
BR112017001926A2 (pt) processamento de eletrofluido
FR3024297B1 (fr) Goulotte